| DIRECT COMPETITOR COMPARISON | |
| DRRX | IFLO | KG | Pvt1 | Industry | | Market Cap: | 195.18M | N/A | 2.94B | N/A | 161.24M | | Employees: | 171 | N/A | 3,381 | 8051 | 103 | | Qtrly Rev Growth (yoy): | 26.30% | N/A | 19.30% | N/A | 20.50% | | Revenue (ttm): | 27.14M | N/A | 1.69B | 102.30M1 | 46.74M | | Gross Margin (ttm): | -93.39% | N/A | 68.58% | N/A | 68.58% | | EBITDA (ttm): | -38.00M | N/A | 533.79M | N/A | -7.12M | | Oper Margins (ttm): | -149.71% | N/A | 21.23% | N/A | 2.25% | | Net Income (ttm): | -40.05M | N/A | -472.15M | N/A | N/A | | EPS (ttm): | -0.487 | N/A | -1.933 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | N/A | N/A | 17.12 | | PEG (5 yr expected): | N/A | N/A | 1.6 | N/A | 1.04 | | P/S (ttm): | 7.45 | N/A | 1.76 | N/A | 4.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.35 | -0.27% | 57.03B | 12.29 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.94 | 0.04% | 13.57B | 15.71 | | Genzyme Corp. | GENZ | 50.70 | -0.72% | 13.45B | 28.91 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.11 | -0.97% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.78 | -0.34% | 8.88B | 1015.92 | | Teva Pharmaceutical Industries Limited | TEVA | 52.79 | -0.17% | 46.51B | 48.30 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.09 | 0.35% | 3.94B | 19.12 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | -1.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | -0.78% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.17 | -0.44% | 146.62B | 15.09 | | Johnson & Johnson | JNJ | 62.84 | -0.08% | 173.38B | 13.72 | | GlaxoSmithKline plc | GSK | 41.47 | -1.87% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.96 | -1.22% | 99.12B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.60 | 0.40% | 126.28B | 16.65 | | RHHBY.PK | 40.92 | -1.30% | N/A | N/A | | AstraZeneca plc | AZN | 44.83 | -1.02% | 65.00B | 9.00 | | Abbott Laboratories | ABT | 54.49 | 0.76% | 84.28B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 25.31 | -0.28% | 50.14B | 13.09 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | KG | | King Pharmaceuticals Financial Gauge Analysis for September 2009 Quarter
Mon 7:09am -
at Seeking Alpha | | • | KG | | Your First Move For Friday November 27th
Wed, Nov 25 -
at CNBC | | • | IFLO | | Kimberly-Clark to buy medical device maker I-Flow
Tue, Nov 24 -
AP | | • | IFLO | | I FLOW CORP /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Tue, Nov 24 -
EDGAR Online | | • | IFLO | | Kimberly-Clark Corporation Completes Tender Offer for I-Flow Corporation
Tue, Nov 24 -
PR Newswire | | • | KG | | Monday Options Recap
Mon, Nov 23 -
at Seeking Alpha | | • | KG | | Which Drug Companies Could Be Private-Equity Targets?
Mon, Nov 23 -
at The Wall Street Journal Online | | • | KG | | King, Donaldson Lead High-Flying Stocks
Fri, Nov 20 -
at TheStreet.com | | • | KG | | 'Fast Money' Recap: Playing Defense
Thu, Nov 19 -
at TheStreet.com | | • | KG | | Market Winners & Losers: King Pharmaceuticals, MBIA
Thu, Nov 19 -
at Fox Business | | • | KG | | Your First Move For Friday November 20th
Thu, Nov 19 -
at CNBC | | • | IFLO | | Kimberly-Clark Corporation Completes Initial Tender Offer for I-Flow Corporation
Wed, Nov 18 -
PR Newswire | | • | IFLO | | Pain Device Warning
Mon, Nov 16 -
at The Wall Street Journal Online | | | All Headlines for these symbols... |
|
|
|
0.34% Nasdaq 
0.08 (3.43%) 
Competitors
